{
    "clinical_study": {
        "@rank": "25319", 
        "brief_summary": {
            "textblock": "RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal\n      cells.\n\n      PURPOSE: Phase I trial to study the effectiveness of the BL22 immunotoxin in treating\n      patients who have non-Hodgkin's lymphoma or chronic lymphocytic leukemia."
        }, 
        "brief_title": "BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", 
        "condition": [
            "Leukemia", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Follicular"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the toxicity and therapeutic efficacy of recombinant BL22 immunotoxin in\n           patients with CD22-positive B-cell non-Hodgkin's lymphoma or chronic lymphocytic\n           leukemia.\n\n        -  Determine the pharmacokinetics, including the terminal elimination serum half-life area\n           under the curve and volume of distribution, of recombinant BL22 immunotoxin in these\n           patients.\n\n        -  Determine the immunogenicity of recombinant BL22 immunotoxin in these patients.\n\n        -  Determine the effect of recombinant BL22 immunotoxin on various components of the\n           circulating cellular immune system in these patients.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive recombinant BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5.\n      Patients may be retreated at least every 20 days for up to 25 courses in the absence of\n      disease progression and sufficient neutralizing antibodies.\n\n      Cohorts of 3-6 patients receive escalating doses of recombinant BL22 immunotoxin until the\n      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at\n      which 2 of 6 patients experience dose-limiting toxicity.\n\n      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed chronic lymphocytic leukemia or prolymphocytic leukemia:\n\n          -  Failed prior standard chemotherapy and treatment is medically indicated as evidenced\n             by the following:\n\n          -  Progressive disease-related symptoms\n\n          -  Progressive cytopenias due to marrow involvement\n\n          -  Progressive or painful splenomegaly or adenopathy\n\n          -  Rapidly increasing lymphocytosis\n\n          -  Autoimmune hemolytic anemia or thrombocytopenia\n\n          -  Increased frequency of infections OR\n\n          -  Confirmed CD22+ B-cell indolent non-Hodgkin's lymphoma\n\n          -  Stages II-IV that have failed at least 1 prior standard therapy and treatment is\n             medically indicated\n\n          -  No patients whose serum neutralizes BL22 or PE38 in tissue culture, due to antitoxin\n             or antimouse-IgG antibodies\n\n          -  No central nervous system disease requiring treatment\n\n          -  If the patient is non-leukemic, the absolute neutrophil count must be greater than\n             1,000/mm3 and the platelet count greater than 40,000/mm3\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 6 months\n\n        Hematopoietic:\n\n          -  See Disease Characteristics\n\n        Hepatic:\n\n          -  ALT and AST less than 5 times upper limit of normal\n\n        Renal:\n\n          -  Adequate renal function\n\n        Pulmonary:\n\n          -  Adequate pulmonary function\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  HIV negative\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Prior bone marrow transplantation allowed\n\n          -  At least 3 weeks since prior interferon for malignancy\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior cytotoxic chemotherapy for malignancy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 3 weeks since prior radiotherapy for malignancy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  At least 3 weeks since prior retinoids\n\n          -  At least 3 weeks since prior systemic therapy for cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00021593", 
            "nct_id": "NCT00024115", 
            "org_study_id": "CDR0000068892", 
            "secondary_id": [
                "NCI-01-C-0213", 
                "NCI-5336"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "BL22 immunotoxin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "antibody therapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "biological response modifier therapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "immunotoxin therapy", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunologic Factors", 
                "Immunotoxins"
            ]
        }, 
        "keyword": [
            "refractory chronic lymphocytic leukemia", 
            "B-cell chronic lymphocytic leukemia", 
            "stage III grade I follicular small cleaved cell lymphoma", 
            "stage III grade II follicular mixed cell lymphoma", 
            "stage III adult diffuse small cleaved cell lymphoma", 
            "stage IV grade I follicular small cleaved cell lymphoma", 
            "stage IV grade II follicular mixed cell lymphoma", 
            "stage IV adult diffuse small cleaved cell lymphoma", 
            "recurrent grade I follicular small cleaved cell lymphoma", 
            "recurrent grade II follicular mixed cell lymphoma", 
            "recurrent grade III follicular large cell lymphoma", 
            "recurrent adult diffuse small cleaved cell lymphoma", 
            "recurrent adult diffuse mixed cell lymphoma", 
            "recurrent adult diffuse large cell lymphoma", 
            "recurrent adult immunoblastic large cell lymphoma", 
            "recurrent adult lymphoblastic lymphoma", 
            "recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma", 
            "prolymphocytic leukemia", 
            "contiguous stage II grade I follicular small cleaved cell lymphoma", 
            "contiguous stage II grade II follicular mixed cell lymphoma", 
            "contiguous stage II adult diffuse small cleaved cell lymphoma", 
            "noncontiguous stage II grade I follicular small cleaved cell lymphoma", 
            "noncontiguous stage II grade II follicular mixed cell lymphoma", 
            "noncontiguous stage II adult diffuse small cleaved cell lymphoma", 
            "stage III diffuse small lymphocytic/marginal zone lymphoma", 
            "contiguous stage II diffuse small lymphocytic/marginal zone lymphoma", 
            "noncontiguous stage II diffuse small lymphocytic/marginal zone lymphoma", 
            "stage IV diffuse small lymphocytic/marginal zone lymphoma", 
            "recurrent diffuse small lymphocytic/marginal zone lymphoma", 
            "recurrent mantle cell lymphoma"
        ], 
        "lastchanged_date": "January 11, 2007", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892-1182"
                }, 
                "name": "Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "Robert Kreitman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00024115"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2006"
    }, 
    "geocoordinates": {
        "Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support": "38.985 -77.095"
    }
}